Navigation Links
deCODE Genetics Announces Full-year 2007 Financial Results
Date:3/12/2008

our leadership in human genetics. We have brought to market pioneering DNA-based risk assessment tests for type 2 diabetes, early-onset heart attack, atrial fibrillation/stroke, prostate cancer, and glaucoma, and launched the world's first personal genome analysis service, deCODEme(TM). With these diagnostics and personal genome products on the market, and others to be launched in the months ahead, deCODE is focused on capturing the potential of our competitive advantage in human genetics, at the same time as we seek partnerships to advance our therapeutics programs and to most efficiently allocate spending and spread risk. We are committed to executing on this strategy and to ensuring we have the cash resources to maximize the creation of value for the company and its shareholders," said Kari Stefansson, CEO of deCODE.

Fourth quarter 2007 results

Revenue for the quarter ended December 31, 2007 was $13.3 million, compared to $11.5 million for the fourth quarter 2006. Net loss for the fourth quarter 2007 was $32.4 million, compared to $23.2 million for the same period a year ago. $7.8 million of the fourth quarter net loss figure is due to ARS- related impairment charges. Research and development expense for proprietary programs decreased to $12.6 million for the fourth quarter 2007 from $14.2 million for the same period in 2006. For the fourth quarter 2007, selling, general and administrative expenses were $7.7 million versus $8.6 million for the fourth quarter 2006.

Key highlights over the past year include:

Product Development

-- Diagnostics. Over the past year deCODE has brought to market its first

DNA-based reference laboratory diagnostic tests for gauging risk of

several major diseases. These pioneering tests are based upon deCODE's

discoveries of major genetic risk factors for many of the major

challenges to public health, and provide a new means for assessing

individual ris
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... WA (PRWEB) March 02, 2015 Sterlitech ... flow flat-sheet testing system at the 2015 AMTA Membrane ... a culmination of a decade’s worth of engineering and ... compatible with a wide range of applications across an ... versatile enough to meet the dynamic needs of researchers ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... has been made aware of a fraudulent press release ... GlobeNewswire, purporting to be from Immunovaccine. This press release ... with Gilead Science, Inc. The press release did ... to the information contained within the press release. ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... 16 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... of the company,s HIV tropism assay were presented ... Drug Resistance Workshop,in Sitges, Spain. Trofile was introduced ... in class CCR5 antagonist, in,August 2007. Recent enhancements ...
... /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ... compound in clinical trial in patients with ... the European Hematology Association,held in Copenhagen, Denmark ... Director R&D, Biology, presented data on,PBI-1402 in ...
... Inc. (Nasdaq: ALXN ) today announced that ... of Alexion,Pharmaceuticals, will present at the William Blair ... a.m., local time (10:10 a.m., eastern) on,Thursday, June ... Sinha,s remarks will be available live. You can,access ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... This news release is available in French . ... of the administration and dosage of antipsychotics may influence their ... universitaire en sant mentale de Montral and Universit de Montral. ... their ability to get into the bloodstream after being absorbed. ...
... 8, 2013) According to Gertrude Stein, "A rose is ... might not be the case when it comes to the ... have found that as much as 30 percent of the ... individuals. This substantial variation is in turn reflected by variability ...
... in Lyon, a French city famed for its cuisine, have ... The breakthrough suggests a better way of producing the ... a few decades, it could even help the world meet ... greenhouse effect and climate change. It also ...
Cached Biology News:How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy? 2Extensive variability in olfactory receptors influences human odor perception 2Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 2Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 3Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 4Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 5Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 6
... Plus accurately and conveniently controls the temperature at ... different temperature levels up to 99 C*, with ... as low as 5 C. The thermoblocks for ... tubes, and microplates enable a high degree of ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
...
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
Biology Products: